|Articles|April 4, 2023
Calyx Announces Partnership With Ceretype Neuromedicine
Ceretype platform utilizes novel functional MRI and AI.
Advertisement
Calyx has announced a strategic partnership with Ceretype Neuromedicine, Inc., whose novel functional MRI (fMRI) platform incorporates optimal image acquisition and advanced analytics to de-risk and accelerate the development of psychiatric and neurological therapies.
The Ceretype platform utilizes fMRI and artificial intelligence to connect neural circuitry to patient behaviors and treatment outcomes, delivering the objective biologic endpoints for more precise measurement of treatment effects during central nervous system drug development.
Reference
Calyx Delivers Imaging Biomarkers to Advance Neuropsychiatric Treatment Development. (2023, April 4). Cision PR Newswire.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
Q&A: Strategies for Successful Global Clinical Trial DeliverySeptember 12th 2025
Vabysmo Shows Long-Term Efficacy and Safety in Wet AMD, PCV PatientsSeptember 12th 2025
Latest NIMBLE Study Results Highlight Progress in gMG ResearchSeptember 12th 2025
ACT Brief Episode 8: Expert Insights on the Future of Obesity Drug TrialsSeptember 11th 2025
Advertisement
Advertisement
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
